Showing 1981-1990 of 2659 results for "".
- ViaLase Closes $40 million Series C Financing to Advance First Femtosecond Laser for the Treatment of Glaucomahttps://modernod.com/news/vialase-closes-40-million-series-c-financing-to-advance-first-femtosecond-laser-for-the-treatment-of-glaucoma/2482192/ViaLase has closed a Series C financing with proceeds of approximately $40 million to continue advancement of clinical, regulatory, and commercial milestones of the company's ViaLase Laser. If approved, the ViaLase Laser will be the first femtosecond laser used for the tre
- Terry Kim, MD, Joins Alcon as Chief Medical Officer and Head of Global Medical Safetyhttps://modernod.com/news/terry-kim-md-joins-alcon-as-chief-medical-officer-and-head-of-global-medical-safety/2482182/Terry Kim, MD, Professor of Ophthalmology at Duke University Eye Center, will join Alcon in April as Chief Medical Officer (CMO) and Head of Global Medical Safety. Dr. Kim serves as Duke Eye Center’s Chief of the Cornea and External Disease Division, Director of the Refractive Sur
- BlueRock Therapeutics and Foundation Fighting Blindness Partner for IRD Studyhttps://modernod.com/news/bluerock-therapeutics-and-foundation-fighting-blindness-partner-for-ird-study/2482178/BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer, and Foundation Fighting Blindness announced a collaboration to add a new cohort to the Foundation’s 'Uni-Rare natural history study' of people living with inherited retinal diseases (I
- Richard Lindstrom, MD, to Lead Eye Care Biopharmaceutical Company Surface Ophthalmicshttps://modernod.com/news/richard-lindstrom-md-to-lead-new-eye-care-biopharmaceutical-company-surface-ophthalmics/2482161/Surface Ophthalmics announced the appointment of Richard Lindstrom, MD, as Founder and Chairman. Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, PA. Dr. Lindstrom will lead in partnership with Surface’s Board of Directors, including
- Telios Pharma Announces Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/telios-pharma-announces-successful-phase-2-results-for-tl-925-a-novel-treatment-for-dry-eye-disease/2482150/Telios Pharma announced topline results from its phase 2 study assessing TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with moderate to severe dry eye disease (DED). This proof-of-concept, multicenter, randomized, double-masked study evaluated the
- Glaukos' iDose TR Now Commercially Availablehttps://modernod.com/news/glaukos-idose-tr-now-commercially-available/2482139/Glaukos' iDose TR (travoprost intracameral implant 75 mcg), which uses Celanese’s VitalDose EVA (Ethylene Vinyl Acetate) to provide sustained drug release for the treatment of glaucoma, is now commerically available, according to Celanese. The iDo
- PulseSight Therapeutics Launches to Advance Non-Viral Gene Therapies for Severe Retinal Diseaseshttps://modernod.com/news/pulsesight-therapeutics-launches-to-advance-non-viral-gene-therapies-for-severe-retinal-diseases/2482134/PulseSight Therapeutics launched today with a portfolio that includes two first-in-class late-stage preclinical drugs for wet and dry age-related macular diseases (AMD), including geographic atrophy (GA). PulseSight’s proprietary non-viral gene therapy ocu
- CoFi Announces Market-Wide Availability of its Multi-Provider Financing Solution with CareCredithttps://modernod.com/news/cofi-announces-market-wide-availability-of-its-multi-provider-financing-solution-with-carecredit/2482133/CoFi announced that patient payments with the CareCredit credit card can now be processed through CoFi’s multi-party payments platform. This market-wide availability follows a successful beta period involving joint CoFi and CareCredit customers. “We’ve
- Ocular Therapeutix Announces Board of Directors and Leadership Updateshttps://modernod.com/news/ocular-therapeutix-announces-board-of-directors-and-leadership-updates/2482128/Ocular Therapeutix announced Board of Directors and leadership updates with the addition of Pravin U. Dugel, MD as Executive Chairman; and the additions of Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, MBBS, PhD, to the Ocular management
- Eversight Partners with Emmecell Biotech to Advance Ocular Cell Therapieshttps://modernod.com/news/eversight-partners-with-emmecell-biotech-to-advance-ocular-cell-therapies/2482124/Global nonprofit eye bank Eversight has partnered with biotech company Emmecell to advance cell therapies for the treatment of eye disease. Financial terms of the deal were not disclosed. Emmecell’s minimally invasive cell therapy injects healthy corneal